[1]
Fajloun Z, Kovacic H, Annweiler C, Wu Y, Cao Z, Sabatier JM. SARS-CoV-2-induced neurological disorders in symptomatic COVID-19 and long COVID patients: Key role of brain renin-angiotensin system. Infect Disord Drug Targets 2022; 22(5): e060422203203.
[http://dx.doi.org/10.2174/1871526522666220406124618] [PMID: 35388764]
[http://dx.doi.org/10.2174/1871526522666220406124618] [PMID: 35388764]
[2]
El-Arif G, Farhat A, Khazaal S, et al. The renin-angiotensin system: A key role in SARS-CoV-2-induced COVID-19. Molecules 2021; 26(22): 6945.
[http://dx.doi.org/10.3390/molecules26226945] [PMID: 34834033]
[http://dx.doi.org/10.3390/molecules26226945] [PMID: 34834033]
[3]
El-Arif G, Khazaal S, Farhat A, et al. Angiotensin II type I receptor (AT1R): The gate towards COVID-19-associated diseases. Molecules 2022; 27(7): 2048.
[http://dx.doi.org/10.3390/molecules27072048] [PMID: 35408447]
[http://dx.doi.org/10.3390/molecules27072048] [PMID: 35408447]
[4]
Khazaal S, Harb J, Rima M, et al. The pathophysiology of long COVID throughout the renin-angiotensin system. Molecules 2022; 27(9): 2903.
[http://dx.doi.org/10.3390/molecules27092903] [PMID: 35566253]
[http://dx.doi.org/10.3390/molecules27092903] [PMID: 35566253]
[5]
Annweiler C, Cao Z, Papon N, Kovacic H, Sabatier JM. Counter-regulatory renin-angiotensin system: An important line of research to understand and limit the severity of COVID-19. Infect Disord Drug Targets 2022; 22(2): e100921196331.
[http://dx.doi.org/10.2174/1871526521666210910063227] [PMID: 34515015]
[http://dx.doi.org/10.2174/1871526521666210910063227] [PMID: 34515015]
[6]
Harb J, Debs N, Rima M, et al. SARS-CoV-2, COVID-19, and reproduction: Effects on fertility, pregnancy, and neonatal life. Biomedicines 2022; 10(8): 1775.
[http://dx.doi.org/10.3390/biomedicines10081775] [PMID: 35892675]
[http://dx.doi.org/10.3390/biomedicines10081775] [PMID: 35892675]
[7]
Smith G, Missailidis S. Cancer, inflammation and the AT1 and AT2 receptors. J Inflamm 2004; 1(1): 3.
[http://dx.doi.org/10.1186/1476-9255-1-3] [PMID: 15813980]
[http://dx.doi.org/10.1186/1476-9255-1-3] [PMID: 15813980]
[8]
Rhodes CE, Denault D, Varacallo M. Physiology, Oxygen Transport.In: StatPearls. Treasure Island, FL: StatPearls Publishing 2022.
[9]
Besa EC. Physiological changes in blood volume. CRC Crit Rev Clin Lab Sci 1975; 6(1): 67-79.
[http://dx.doi.org/10.3109/10408367509151565] [PMID: 1095303]
[http://dx.doi.org/10.3109/10408367509151565] [PMID: 1095303]
[10]
Glancy B, Kane DA, Kavazis AN, Goodwin ML, Willis WT, Gladden LB. Mitochondrial lactate metabolism: History and implications for exercise and disease. J Physiol 2021; 599(3): 863-88.
[http://dx.doi.org/10.1113/JP278930] [PMID: 32358865]
[http://dx.doi.org/10.1113/JP278930] [PMID: 32358865]
[11]
Koga S, Rossiter HB, Heinonen I, Musch T, Poole DC. Dynamic heterogeneity of exercising muscle blood flow and O2 utilization. Med Sci Sports Exerc 2014; 46(5): 860-76.
[http://dx.doi.org/10.1249/MSS.0000000000000178] [PMID: 24091989]
[http://dx.doi.org/10.1249/MSS.0000000000000178] [PMID: 24091989]
[12]
van der Zwaard S, Brocherie F, Jaspers RT. Under the hood: Skeletal muscle determinants of endurance performance. Front Sports Act Living 2021; 3: 719434.
[http://dx.doi.org/10.3389/fspor.2021.719434] [PMID: 34423293]
[http://dx.doi.org/10.3389/fspor.2021.719434] [PMID: 34423293]
[13]
Blomstrand E, Kaijser L, Martinsson A, Bergh U, Ekblom B. Temperature-induced changes in metabolic and hormonal responses to intensive dynamic exercise. Acta Physiol Scand 1986; 127(4): 477-84.
[http://dx.doi.org/10.1111/j.1748-1716.1986.tb07931.x] [PMID: 3751634]
[http://dx.doi.org/10.1111/j.1748-1716.1986.tb07931.x] [PMID: 3751634]
[14]
Balogun TA, Chukwudozie OS, Ogbodo UC, et al. Discovery of putative inhibitors against main drivers of SARS-CoV-2 infection: Insight from quantum mechanical evaluation and molecular modeling. Front Chem 2022; 10: 964446.
[http://dx.doi.org/10.3389/fchem.2022.964446] [PMID: 36304744]
[http://dx.doi.org/10.3389/fchem.2022.964446] [PMID: 36304744]
[15]
Annweiler C, Cao Z, Wu Y, et al. Counter-regulatory ‘renin-angiotensin’ system-based candidate drugs to treat COVID-19 diseases in SARS-CoV-2-infected patients. Infect Disord Drug Targets 2020; 20(4): 407-8.
[http://dx.doi.org/10.2174/22123989MTA2cNzIlw] [PMID: 32418532]
[http://dx.doi.org/10.2174/22123989MTA2cNzIlw] [PMID: 32418532]
[16]
Mehraeen E, Najafi Z, Hayati B, et al. Current treatments and therapeutic options for COVID-19 patients: A systematic review. Infect Disord Drug Targets 2021; 21.
[http://dx.doi.org/10.2174/1871526521666210726150435] [PMID: 34313204]
[http://dx.doi.org/10.2174/1871526521666210726150435] [PMID: 34313204]